Items Tagged ‘Breast Cancer’

December 14th, 2017

Acupuncture Reduces Aromatase Inhibitor Joint Pain in Women with Breast Cancer

By

According to a well designed study presented at the 2017 San Antonio Breast Cancer Symposium acupuncture is effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.1 Stiffness and joint pain is a well documented concern of women undergoing AI therapy for the treatment and prevention of […]

View full entry

Tags: Acupuncture, Aromatase, Arthralgia, Arthritis, Breast Cancer, Complementary Alternative Medicine, inhibitor, joint pain, News


December 12th, 2017

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer

By

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali® (ribociclib) in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2017 Annual San Antonio Breast Cancer […]

View full entry

Tags: advanced breast cancer, Breast Cancer, cyclin-dependent kinase, inhibitor, kisqali, MONELESSA 7, News, Precision Cancer Medicine, premenopausal, ribociclib, San Antonio Breast Cancer Symposium


December 12th, 2017

Keytruda Immunotherapy Shows Promise for Patients With Herceptin-resistant Breast Cancer

By

A combination of Keytruda (pembrolizumab) and Herceptin (trastuzumab), tested in patients with Herceptin-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for Keytruda, according to data presented at the 2017 San Antonio Breast Cancer Symposium. About HER2-Positive Breast Cancer About one in five […]

View full entry

Tags: Breast Cancer, Herceptin-resistant, immunotherapy, keytruda, News, pembrolizumab, Precision Cancer Medicine, SABCS, trastuzumab


November 14th, 2017

Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer

By

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their older counterparts, researchers however have more recently begun to focus on improving the treatment outcomes for […]

View full entry

Tags: advanced breast cancer, Breast Cancer, CDK4/6, cyclin-dependent kinase 4 and 6, kisqali, MONALEESA-7, News, Precision Cancer Medicine, ribociclib


November 1st, 2017

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer

By

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. About HER2-Positive Breast Cancer Approximately 20% to 25% of breast cancers over-express the HER2 protein. HER2-positive […]

View full entry

Tags: Breast Cancer, HER-2, HER4 Positive Early Stage Breast Cancer, herceptin, Nerlynx HER1, News, Precision Cancer Medicine, trastuzumab


October 30th, 2017

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer

By

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer progression compared to treatment with fulvestrant alone in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), […]

View full entry

Tags: 4 & 6 inhibitor, abemaciclib, advanced breast cancer, Breast Cancer, CDK, cyclin-dependent kinase, News, Phase 3 MONARCH 2, Precision Cancer Medicine, Verzenio


October 26th, 2017

Radius Health Receives FDA Fast Track Designation for Elacestrant

By

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast cancer. Fast Track designation is a process designed to facilitate the development and expedite the review of new therapies to […]

View full entry

Tags: Breast Cancer, Elacestrant, News, RAD1901


October 12th, 2017

Immunotherapy Active Against Triple-Negative Breast Cancer

By

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that they are estrogen-receptor negative (ER-), […]

View full entry

Tags: atezolizumab, Breast Cancer, checkpoint inhibitor, immunotherapy, keytruda, News, PD-1, pembrolizumab, Precision Cancer Medicine, Tecentriq, Triple Negative Breast Cancer


October 10th, 2017

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations

By

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition that causes up to 3% of all breast cancers. BRCA + breast cancer is particularly […]

View full entry

Tags: BRCA breast cancer, Breast Cancer, lynparza, News, olaparib, PARP inhibitor, Precision Cancer Medicine


October 5th, 2017

FDA approves new treatment for certain advanced or metastatic breast cancers

By

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine […]

View full entry

Tags: abemaciclib, Breast Cancer, fulvestrant, hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, Metastatic Breast Cancer, News, Precision Cancer Medicine, Verzenio


September 13th, 2017

Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths

By

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening mammography. Published early online in Cancer, […]

View full entry

Tags: Annual Mammography, Breast Cancer, breast cancer screening, early detection, mammogram, News, Prevents Death from breast cancer


August 30th, 2017

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with Herceptin and Perjeta and have disease progression after ado-trastuzumab (T-DM1). Breakthrough Therapy designation is designed to […]

View full entry

Tags: ado-trastuzumab, Breast Cancer, DS-8201, HER2-positive, herceptin, locally advanced, Metastatic Breast Cancer, News, perjeta, Precision Cancer Medicine, T-DM1


August 1st, 2017

Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence

By

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-center […]

View full entry

Tags: Breast Cancer, breast surgery, early-stage breast cancer, News, Nipple-Sparing Mastectomy


July 26th, 2017

Balance and Gait is Negatively Impacted By Chemotherapy Treatment

By

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research […]

View full entry

Tags: Balance, Breast Cancer, Chemotherapy, News, side effects


July 18th, 2017

FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer

By

The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the ExteNET trial (NCT00878709), a multicenter, randomized, double-blind, placebo-controlled trial of Nerlynx following adjuvant trastuzumab treatment. Women (n=2,840) with early-stage HER2-positive breast cancer […]

View full entry

Tags: Breast Cancer, HER2, neratinib, Nerlynx, News